Pharmaceutical Executive-11-01-2010

Pharmaceutical Executive
Features

November 18, 2010

New CER tools grant payers the evidence they need to control drug costs

Pharmaceutical Executive
Sponsored Content

November 01, 2010

Once silent, an emerging market raises its voice

Pharmaceutical Executive
Features

November 01, 2010

Harvard professor Daniel Carpenter offers a piercing analysis of the FDA and sheds light on its biggest challenges

Pharmaceutical Executive
Columns

November 01, 2010

With all the money and momentum focused on medicines in emerging markets, it may be time to take a closer look at business opportunities in this more familiar neighbor to the East

Pharmaceutical Executive

There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?

Pharmaceutical Executive
From the Editor

November 01, 2010

The FDA process itself is looking more like the unsavory 'sausage factory' associated with drafting partisan legislation

Pharmaceutical Executive
Columns

November 01, 2010

The CEO should be able to communicate the vision of a merger-strategically, financially, operationally, and with the entire organization in mind

Pharmaceutical Executive
Columns

November 01, 2010

PCORI is independent and transparent and likely to alter methods for assesssing the value of new therapies

Pharmaceutical Executive
Columns

November 01, 2010

Pharm Exec sits down with an expert on regional marketing to ascertain what it takes to drive strong brand results

Pharmaceutical Executive
Back Page

November 01, 2010

A timeline of some of the landmark legislation, court decisions, and drug scandals that helped forge the FDA